成都、北京等地于1977年先后用麦迪霉素肠溶糖衣片治疗呼吸道感染及化脓性皮肤病,发现该药有疗效好、副作用较少、属非诱导耐药型抗生素,且部份对红霉素耐药的金黄色葡萄球菌仍对麦迪霉素敏感等优点。四川抗菌素工业研究所为提高麦迪霉素血浓度,扩大其应用范围,于1979年试制成功麦迪霉素酒石酸盐静脉注射剂。现将我们对其所进行的临床及实验研究结果报告如下。 Chengdu, Beijing and other places in 1977 with midemycin enteric-coated tablets in the treatment of respiratory tract infections and suppurative skin disease and found that the drug has good efficacy, fewer side effects, is a non-induced drug-resistant antibiotics, and some of the red Mycotoxin-resistant Staphylococcus aureus is still sensitive to midecamycin and other advantages. Sichuan Institute of Antibiotics to increase the blood concentration of midecamycin, to expand its scope of application, in 1979, trial success mimenmycin tartrate intravenous injection. Now we carry out their clinical and experimental findings are reported below.